• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

滤泡细胞来源的甲状腺癌的侵袭性变异型:概述。

Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.

机构信息

Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98124, Messina, Italy.

Department of Pathology, Foundation "Agostino Gemelli", University Hospital IRCCS, 00168, Rome, Italy.

出版信息

Endocrine. 2022 Oct;78(1):1-12. doi: 10.1007/s12020-022-03146-0. Epub 2022 Jul 21.

DOI:10.1007/s12020-022-03146-0
PMID:35864338
Abstract

PURPOSE

The incidence of thyroid carcinoma has increased globally in the past years. Papillary thyroid carcinoma (PTC) is the most frequent neoplasm of the thyroid gland comprehending the 90% of the thyroid carcinoma and has an indolent clinical behaviour. However, some variants of follicular cell-derived thyroid carcinoma, including variants of classic of PTC, have been identified that show a more aggressive biological behaviour. An accurate diagnosis of these entities is crucial for planning a more aggressive treatment and improving patients' prognosis of patients. The aim of this review is to present the main clinical, histological, and molecular features of aggressive variants of follicular cell-derived thyroid carcinoma, and to provide useful histological parameters for determining the most suitable therapeutic strategy for patients affected by these forms.

RESULTS

Variants of classic PTC such as the diffuse sclerosing variant (DSV), the tall cell variant (TCV), the columnar cell variant (CCV), the solid/trabecular variant (STV) and the hobnail variant (HV), and other variants of follicular cell-derived thyroid carcinoma, such as poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC), are associated with aggressive behaviour.

CONCLUSIONS

The correct identification and diagnosis of aggressive variants of follicular cell-derived thyroid carcinoma is important, as they allow the clinician to adopt the most refined therapeutic strategies in order to the survival of the patients.

摘要

目的

近年来,全球甲状腺癌的发病率有所增加。甲状腺乳头状癌(PTC)是甲状腺最常见的肿瘤,占甲状腺癌的 90%,具有惰性的临床行为。然而,已经确定了一些滤泡细胞来源的甲状腺癌的变体,包括经典 PTC 的变体,这些变体表现出更具侵袭性的生物学行为。准确诊断这些实体对于规划更具侵袭性的治疗方案和改善患者预后至关重要。本综述的目的是介绍侵袭性滤泡细胞来源的甲状腺癌变体的主要临床、组织学和分子特征,并提供有用的组织学参数,以确定最适合这些形式患者的治疗策略。

结果

经典 PTC 的变体,如弥漫性硬化变体(DSV)、高细胞变体(TCV)、柱状细胞变体(CCV)、实性/小梁状变体(STV)和钉状细胞变体(HV),以及其他滤泡细胞来源的甲状腺癌变体,如低分化甲状腺癌(PDTC)和间变性甲状腺癌(ATC),与侵袭性行为相关。

结论

正确识别和诊断侵袭性滤泡细胞来源的甲状腺癌变体非常重要,因为它们可以让临床医生采用最精细的治疗策略,以提高患者的生存率。

相似文献

1
Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.滤泡细胞来源的甲状腺癌的侵袭性变异型:概述。
Endocrine. 2022 Oct;78(1):1-12. doi: 10.1007/s12020-022-03146-0. Epub 2022 Jul 21.
2
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
3
Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.贝塞斯达分类法是细针穿刺报告的重要指南,尤其对诊断甲状腺乳头状癌的侵袭性变体具有高度预测性。
Cytopathology. 2017 Aug;28(4):259-267. doi: 10.1111/cyt.12384. Epub 2016 Sep 25.
4
Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves' Disease.Graves 病中高细胞型甲状腺乳头状癌的发生率更高。
Thyroid. 2014 Feb;24(2):347-54. doi: 10.1089/thy.2013.0133. Epub 2013 Sep 11.
5
Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma.液基细胞学提高了甲状腺乳头状癌高细胞变体的术前诊断准确性。
Diagn Cytopathol. 2014 Jan;42(1):11-7. doi: 10.1002/dc.23007. Epub 2013 Jun 11.
6
Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas.致命性非间变性滤泡细胞源性甲状腺癌的临床病理特征
Thyroid. 2016 Nov;26(11):1588-1597. doi: 10.1089/thy.2016.0247. Epub 2016 Sep 7.
7
Aggressive Variants of Papillary Thyroid Carcinoma: Hobnail, Tall Cell, Columnar, and Solid.侵袭性甲状腺乳头状癌的变异型:鞋钉样、高柱状、柱状和实性。
Adv Anat Pathol. 2018 May;25(3):172-179. doi: 10.1097/PAP.0000000000000184.
8
The evolving concept of aggressive histological variants of differentiated thyroid cancer.分化型甲状腺癌侵袭性组织学亚型的演变概念。
Semin Diagn Pathol. 2020 Sep;37(5):228-233. doi: 10.1053/j.semdp.2020.03.002. Epub 2020 Mar 17.
9
Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients.侵袭性甲状腺乳头状癌的变异型:43738 例患者中的发病率、特征和生存预测因素。
Ann Surg Oncol. 2012 Jun;19(6):1874-80. doi: 10.1245/s10434-011-2129-x. Epub 2011 Nov 8.
10
Predictive Impact of Metastatic Lymph Node Burden on Distant Metastasis Across Papillary Thyroid Cancer Variants.转移性淋巴结负担对甲状腺乳头状癌各亚型远处转移的预测影响。
Thyroid. 2021 Oct;31(10):1549-1557. doi: 10.1089/thy.2021.0131.

引用本文的文献

1
BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression.BRAF V600E和端粒酶逆转录酶(TERT)启动子突变及其对复发性乳头状甲状腺癌进展的影响。
Endocr Connect. 2025 Jul 30;14(7). doi: 10.1530/EC-25-0116. Print 2025 Jul 1.
2
Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples.病理特征与放射性碘难治性复发性乳头状甲状腺癌之间的关联:基于复发性样本的突变分析
BMC Endocr Disord. 2025 May 20;25(1):134. doi: 10.1186/s12902-025-01954-9.
3
Evaluation of predictive factors for lymph node metastasis in thyroid microcarcinoma: a two-year experience from two high-volume centers.

本文引用的文献

1
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.达拉非尼联合曲美替尼治疗 BRAF V600E 突变型甲状腺未分化癌患者:来自 II 期 ROAR 篮子研究的更新分析。
Ann Oncol. 2022 Apr;33(4):406-415. doi: 10.1016/j.annonc.2021.12.014. Epub 2022 Jan 10.
2
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.卡博替尼治疗放射性碘难治性分化型甲状腺癌(COSMIC-311):一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5.
3
甲状腺微小癌淋巴结转移预测因素的评估:来自两个大型中心的两年经验
Updates Surg. 2025 May 7. doi: 10.1007/s13304-025-02211-3.
4
ITGA3-MET interaction promotes papillary thyroid cancer progression via ERK and PI3K/AKT pathways.整合素α3(ITGA3)与肝细胞生长因子受体(MET)的相互作用通过细胞外信号调节激酶(ERK)和磷脂酰肌醇-3激酶/蛋白激酶B(PI3K/AKT)信号通路促进甲状腺乳头状癌进展。
Ann Med. 2025 Dec;57(1):2483379. doi: 10.1080/07853890.2025.2483379. Epub 2025 Mar 26.
5
Aggressive variants of papillary thyroid carcinoma: characteristics, influencing factors, and effectiveness of radioiodine therapy.甲状腺乳头状癌的侵袭性变体:特征、影响因素及放射性碘治疗的有效性
J Endocrinol Invest. 2025 Apr;48(4):905-918. doi: 10.1007/s40618-024-02507-y. Epub 2024 Dec 9.
6
Aggressive Types of Malignant Thyroid Neoplasms.侵袭性恶性甲状腺肿瘤类型
J Clin Med. 2024 Oct 14;13(20):6119. doi: 10.3390/jcm13206119.
7
Histologic Evaluation of Thyroid Nodules Treated with Thermal Ablation: An Institutional Experience.甲状腺结节热消融治疗的组织学评估:机构经验。
Int J Mol Sci. 2024 Sep 22;25(18):10182. doi: 10.3390/ijms251810182.
8
A Comprehensive Review and Insights into the New Entity of Differentiated High-Grade Thyroid Carcinoma.分化型甲状腺癌新实体的全面综述及深入见解。
Curr Oncol. 2024 Jun 9;31(6):3311-3328. doi: 10.3390/curroncol31060252.
9
Papillary Thyroid Cancer Remodels the Genetic Information Processing Pathways.甲状腺乳头癌重塑遗传信息处理途径。
Genes (Basel). 2024 May 14;15(5):621. doi: 10.3390/genes15050621.
10
Correlation analysis between BRAF mutation and ultrasonic and clinical features of papillary thyroid cancer.BRAF突变与甲状腺乳头状癌超声及临床特征的相关性分析
Heliyon. 2024 Apr 25;10(9):e29955. doi: 10.1016/j.heliyon.2024.e29955. eCollection 2024 May 15.
Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management.
在不具有侵袭性特征的 PTC 中,单纯高细胞百分比不应指导患者的临床管理。
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4109-e4117. doi: 10.1210/clinem/dgab388.
4
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.仑伐替尼治疗间变性甲状腺癌患者的开放性、单臂、多中心、II 期临床试验。
J Clin Oncol. 2021 Jul 20;39(21):2359-2366. doi: 10.1200/JCO.20.03093. Epub 2021 May 7.
5
Genomic profile of columnar cell variant of papillary thyroid carcinoma.甲状腺乳头状癌柱状细胞变体的基因组图谱。
Histopathology. 2021 Oct;79(4):491-498. doi: 10.1111/his.14374. Epub 2021 Jun 15.
6
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.2021 年美国甲状腺协会甲状腺间变性癌患者管理指南。
Thyroid. 2021 Mar;31(3):337-386. doi: 10.1089/thy.2020.0944.
7
A worldwide journey of thyroid cancer incidence centred on tumour histology.以肿瘤组织学为核心的全球甲状腺癌发病率研究之旅。
Lancet Diabetes Endocrinol. 2021 Apr;9(4):193-194. doi: 10.1016/S2213-8587(21)00049-8. Epub 2021 Mar 1.
8
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.仑伐替尼联合帕博利珠单抗是治疗间变性和低分化甲状腺癌的有效治疗选择。
Thyroid. 2021 Jul;31(7):1076-1085. doi: 10.1089/thy.2020.0322. Epub 2021 Apr 15.
9
Recent advances in the management of anaplastic thyroid cancer.间变性甲状腺癌治疗的最新进展
Thyroid Res. 2020 Nov 24;13(1):17. doi: 10.1186/s13044-020-00091-w.
10
The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis.超声甲状腺结节危险分层系统在甲状腺乳头状癌中的评估。一项荟萃分析。
Rev Endocr Metab Disord. 2021 Jun;22(2):453-460. doi: 10.1007/s11154-020-09592-3. Epub 2020 Sep 21.